title: Treatment of HIV infection with raltegravir.
abstract: BACKGROUND
  Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus.
  
  
  OBJECTIVE
  To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability.
  
  
  METHODS
  Data from pharmacokinetic, Phase II and III clinical trials were reviewed.
  
  
  CONCLUSIONS
  Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naïve and -experienced patients.
authors.affiliation: Division of Infectious Diseases, Stony Brook University School of Medicine, Health Sciences Center T15-080, Stony Brook, NY 11794-8153, USA. lisa.chirch@stonybrook.edu
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Chirch
authors.forename: Sidonie
authors.initials: S
authors.lastname: Morrison
authors.forename: Roy T
authors.initials: RT
authors.lastname: Steigbigel
mesh_terms: D002986:Clinical Trials as Topic; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D011760:Pyrrolidinones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068898:Raltegravir Potassium
chemical_list: D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium